Aratana Therapeutics (PETX) Shares Down 26.6%

Shares of Aratana Therapeutics Inc (NASDAQ:PETX) traded down 26.6% during trading on Friday . The stock traded as low as $4.11 and last traded at $4.37. 6,797,889 shares traded hands during mid-day trading, an increase of 411% from the average session volume of 1,329,749 shares. The stock had previously closed at $5.95.

Several analysts have commented on the stock. BidaskClub cut shares of Aratana Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday. Stifel Nicolaus cut shares of Aratana Therapeutics from a “buy” rating to a “hold” rating and decreased their price target for the stock from $8.00 to $5.00 in a research note on Friday. Zacks Investment Research cut shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 14th. HC Wainwright set a $10.00 price target on shares of Aratana Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 5th. Finally, TheStreet upgraded shares of Aratana Therapeutics from a “d” rating to a “c-” rating in a research note on Wednesday, November 21st. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $7.50.

The company has a current ratio of 3.17, a quick ratio of 2.70 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $296.12 million, a price-to-earnings ratio of -4.51 and a beta of 1.78.

Aratana Therapeutics (NASDAQ:PETX) last posted its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. Aratana Therapeutics had a negative net margin of 52.94% and a negative return on equity of 15.08%. The firm had revenue of $21.56 million for the quarter, compared to the consensus estimate of $5.70 million. As a group, equities analysts forecast that Aratana Therapeutics Inc will post -0.25 EPS for the current year.

In other news, insider Ernst Heinen sold 19,308 shares of the business’s stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $6.95, for a total value of $134,190.60. Following the sale, the insider now directly owns 135,694 shares in the company, valued at approximately $943,073.30. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Peter Steven St sold 46,094 shares of the business’s stock in a transaction dated Monday, December 17th. The stock was sold at an average price of $5.85, for a total transaction of $269,649.90. Following the completion of the sale, the insider now owns 516,626 shares in the company, valued at $3,022,262.10. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 77,607 shares of company stock worth $476,116. Insiders own 5.30% of the company’s stock.

Several institutional investors have recently bought and sold shares of PETX. Hollencrest Capital Management bought a new stake in shares of Aratana Therapeutics in the 4th quarter worth about $153,000. American Century Companies Inc. bought a new stake in shares of Aratana Therapeutics in the 2nd quarter worth about $195,000. MetLife Investment Advisors LLC bought a new position in Aratana Therapeutics during the 3rd quarter valued at about $215,000. Bank of Montreal Can grew its holdings in Aratana Therapeutics by 152.9% during the 3rd quarter. Bank of Montreal Can now owns 51,360 shares of the biopharmaceutical company’s stock valued at $301,000 after purchasing an additional 31,053 shares during the last quarter. Finally, Acadian Asset Management LLC grew its holdings in Aratana Therapeutics by 69.8% during the 3rd quarter. Acadian Asset Management LLC now owns 194,746 shares of the biopharmaceutical company’s stock valued at $1,137,000 after purchasing an additional 80,064 shares during the last quarter. Hedge funds and other institutional investors own 67.92% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Aratana Therapeutics (PETX) Shares Down 26.6%” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.com-unik.info/2019/01/11/aratana-therapeutics-petx-shares-down-26-6.html.

About Aratana Therapeutics (NASDAQ:PETX)

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

See Also: What is Cost of Capital?

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit